Viatris Inc. (NASDAQ:VTRS) acquired Aculys Pharma, Inc., gaining rights to develop and commercialize innovative treatments for neurological conditions. With positive analyst coverage and a diverse therapeutic portfolio, VTRS shows promise as a growth stock under $25.